ArticleScientific reports2016
Endothelial cell dysfunction and cardiac hypertrophy in the STOX1 model of preeclampsia.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Guidelines for assessing maternal cardiovascular physiology during pregnancy and postpartum.American journal of physiology. Heart and circulatory physiology · 2024Guideline
- Reduced circulating STOX1 is associated with inflammatory cytokines and insulin resistance in obese individuals: a cross-sectional study.Frontiers in nutrition · 2026Article
- Metabolic theory of preeclampsia: implications for maternal cardiovascular health.American journal of physiology. Heart and circulatory physiology · 2024Review
- Linking genotype to trophoblast phenotype in preeclampsia and HELLP syndrome associated withiScience · 2024Article
- The Clinical Value of Rodent Models in Understanding Preeclampsia Development and Progression.Current hypertension reports · 2023Review
- Impact of Adverse Gestational Milieu on Maternal Cardiovascular Health.Endocrinology · 2023Review
- Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study.ESC heart failure · 2023Article
- Modeling Preeclampsia In Vitro: Polymorphic Variants of STOX1-A/B Genes Can Downregulate CD24 in Trophoblast Cell Lines.International journal of molecular sciences · 2022Article
- Animal models of preeclampsia: investigating pathophysiology and therapeutic targets.American journal of obstetrics and gynecology · 2022Review
- Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Article
- STOX1 deficiency is associated with renin-mediated gestational hypertension and placental defects.JCI insight · 2021Article
- Urothelial Cancer Associated 1 (UCA1) and miR-193 Are Two Non-coding RNAs Involved in Trophoblast Fusion and Placental Diseases.Frontiers in cell and developmental biology · 2021Article
- Long noncoding RNAs: emerging roles in pulmonary hypertension.Heart failure reviews · 2020Review
- Molecular Mechanisms of Trophoblast Dysfunction Mediated by Imbalance between STOX1 Isoforms.iScience · 2020Article
- Disruption of Placental Homeostasis Leads to Preeclampsia.International journal of molecular sciences · 2020Review
- Pregnancy-associated cardiac dysfunction and the regulatory role of microRNAs.Biology of sex differences · 2020Review
- Exploring the Molecular Aetiology of Preeclampsia by Massive Parallel Sequencing of DNA.Current hypertension reports · 2020Review
- Long-term cardiovascular disorders in the STOX1 mouse model of preeclampsia.Scientific reports · 2019Article
- FOXD1 mutations are related to repeated implantation failure, intra-uterine growth restriction and preeclampsia.Molecular medicine (Cambridge, Mass.) · 2019Article
- Alpha-1 microglobulin as a potential therapeutic candidate for treatment of hypertension and oxidative stress in the STOX1 preeclampsia mouse model.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is a disease of pregnancy involving systemic endothelial dysfunction. However, cardiovascular consequences of preeclampsia are difficult to analyze in humans. The objective of the present study is to evaluate the cardiovascular dysfunction induced by preeclampsia by examining the endothelium of mice suffering of severe preeclampsia induced by STOX1 overexpression. Using Next Generation Sequencing on endothelial cells of mice carrying either transgenic or control embryos, we discovered significant alterations of gene networks involved in inflammation, cell cycle, and cardiac hypertrophy. In addition, the heart of the preeclamptic mice revealed cardiac hypertrophy associated with histological anomalies. Bioinformatics comparison of the networks of modified genes in the endothelial cells of the preeclamptic mice and HUVECs exposed to plasma from preeclamptic women identified striking similarities. The cardiovascular alterations in the pregnant mice are comparable to those endured by the cardiovascular system of preeclamptic women. The STOX1 mice could help to better understand the endothelial dysfunction in the context of preeclampsia, and guide the search for efficient therapies able to protect the maternal endothelium during the disease and its aftermath.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.